Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
2019-001655-39Phase 3Active
- Sponsor
- Genmab
- Start
- Dec 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tisotumab vedotin in Cervical Cancer (CC) and cervical cancer (mCC) (2 arms), sponsored by Genmab. Primary endpoint: Overall survival. Started Dec 2019; status: active.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)cervical cancer (mCC)
Beyond the preview
Go deeper on 2019-001655-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001655-39.